BeOne Medicines (ONC) & The Competition Head-To-Head Comparison

BeOne Medicines (NASDAQ:ONC) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare BeOne Medicines to similar companies based on the strength of its analyst recommendations, earnings, profitability, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for BeOne Medicines and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0	1	16	0	2.94
BeOne Medicines Competitors	7798	13891	25784	1038	2.41

BeOne Medicines presently has a consensus price target of $434.79, indicating a potential upside of 4.89%. As a group, “Pharmaceuticals” companies have a potential upside of 24.75%. Given BeOne Medicines’ competitors higher possible upside, analysts plainly believe BeOne Medicines has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

BeOne Medicines has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, BeOne Medicines’ competitors have a beta of -3.71, indicating that their average share price is 471% less volatile than the S&P 500.

Earnings and Valuation

This table compares BeOne Medicines and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BeOne Medicines	$6.61 billion	$286.93 million	52.67
BeOne Medicines Competitors	$5.34 billion	$3.21 billion	553.88

BeOne Medicines has higher revenue, but lower earnings than its competitors. BeOne Medicines is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares BeOne Medicines and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	13.86%	19.04%	10.70%
BeOne Medicines Competitors	-2,380.39%	-218.78%	-15.59%

Summary

BeOne Medicines beats its competitors on 8 of the 13 factors compared.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.